EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth (congenital), or it can be secondary due to brain trauma (acquired). Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. Patients who acquire GHD later in life present with more generalized symptoms, such as increased abdominal fat, decreased levels of energy, and decrease in muscle mass. In young children, certain kinds of cancer treatments, such as cranial radiation, can increase the chances of developing GHD. Other clinical procedures, such as brain surgery, can increase a patient’s chances of developing GHD. GHD may be hereditary, or it may be due to fetal malformation or genetic mutations. Acquired GHD can be caused by trauma to the head or brain and more commonly by a pituitary adenoma.

In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 109,551 cases in 2016 to 112,450 cases in 2026 at an Annual Growth Rate (AGR) of 0.26% in the 7MM. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of GHD in all markets except Germany and Japan. In 2016, the US made up about 48% of all diagnosed prevalent cases of GHD in the 7MM. In 2016, the 5EU made up approximately 40%, and Japan made up nearly 13% of all cases of GHD in the 7MM.

This 10-year epidemiological forecast of GHD is supported by data obtained from international GHD disease monitoring databases, country-specific government sources, as well as peer reviewed studies using market-relevant disease definitions across the 7MM. This forecast provides detailed segmentations within GHD for each market by the patient’s age, sex, and etiological classification (congenital and idiopathic in children, and idiopathic and acquired in adults), thus creating a comprehensive view of the epidemiology of GHD in the 7MM. GlobalData epidemiologists maintained consistent forecast methodology across all seven markets, thus allowing for an accurate and meaningful comparison of included parameters among them.

Scope

The Growth Hormone Deficiency (GHD) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of GHD in children (ages 18 years and younger) and adults (ages 19 years and older) segmented by age and sex. The diagnosed prevalent cases of GHD are further segmented into the classification of the disease (idiopathic and organic in children, and idiopathic and acquired in adults). Organic GHD in children is further segmented into congenital and acquired. GHD in adults is segmented by timing of disease onset: childhood onset GHD and adult onset GHD.

The GHD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The GHD EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global GHD market.

Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.

Identify the percentage of GHD diagnosed prevalent cases by various clinical segmentations.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.3.1 GHD in children

3.3.2 GHD in adults

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for GHD (2016-2026)

3.5.1 Diagnosed Prevalent Cases of GHD

3.5.2 Age-Specific Diagnosed Prevalent Cases of GHD

3.5.3 Sex-Specific Diagnosed Prevalent Cases of GHD

3.5.4 Idiopathic and Organic GHD in Children

3.5.5 Congenital and Acquired GHD Out of Organic GHD in Children

3.5.6 Idiopathic and Acquired GHD in Adults

3.5.7 Onset Timing

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Risk Factors and Comorbidities for GHD

Table 2: Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, for 2016–2026.

Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of GHD, Both Sexes, All Ages, 2016 and 2026

Figure 2: Age-Standardized Diagnosed Prevalence of GHD, Men and Women, All Ages, 2016

Figure 3: Case Flow Map of GHD

Figure 4: Sources Used and Not Used for the Diagnosed Prevalent Cases of GHD in Children

Figure 5: Sources Used and Not Used in the Forecast for Diagnosed Prevalent Cases of GHD in Adults

Figure 6 Sources Used and Not Used in the Forecast for Type of GHD in Children

Figure 7 Sources Used and Not Used in the Forecast for Type of GHD in Adults

Figure 8 Sources Used and Not Used in the Forecast for Onset Timing of GHD in Adults

Figure 9: Age-Specific Diagnosed Prevalent Cases of GHD, Men and Women, All Ages, 2016.

Figure 10: Sex-Specific Diagnosed Prevalent Cases, Men, Women, All Ages, 2016

Figure 11: Diagnosed Prevalent Cases of GHD in Children Segmented into Idiopathic and Organic GHD, Boys and Girls, Ages ≤18 years, 2016

Figure 12: Diagnosed Prevalent Cases of Congenital or Acquired GHD Out of Organic GHD, Boys and Girls, Ages ≤18 years, 2016

Figure 13: Idiopathic and Acquired GHD in Adults, Men and Women, Ages ≥19 Years, 2016.

Figure 14: Diagnosed Prevalent Cases by Onset Timing, Men and Women, Ages ≥19 Years, 2016.

Frequently asked questions

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026 in real time.

  • Access a live EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.